Regeneus inks agreement with high profile Japanese life sciences group
Clinical stage regenerative medicine company Regeneus Ltd (ASX:RGS) has signed a non-binding memorandum of understanding (MOU) with Kyocera Corporation (Kyocera, TYO:6971), a diversified Japanese-based manufacturer with a strong position in the life sciences industry.
The news is a major re-rating for the company as moves towards commercialising its lead stem cell platform technology, Progenza, in Japan. As part of the MOU, Regeneus receives approx. $1.4 million up front.
This news was also well received by the market, reflected in the 19% increase in Regeneus' share price in a day when the broader market was down around 3% at midday.
Japanese giant eyeing Aussie technology
Kyocera’s life sciences business is prominent and they are a major Japanese producer of medical and dental products, including artificial joints for the knee and hip. The company is listed on the Tokyo Stock Exchange, and it has a market capitalisation of approximately 2.5 trillion Japanese yen (AU$35.6 billion) - almost triple the size of Cochlear.
As a regenerative medicine group using stem cell technologies to develop a portfolio of novel cell-based therapies, Regeneus has plenty to offer Kyocera.
More specifically, the company’s regenerative therapies seek to address unmet medical needs in the pain market with a focus on neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza and Sygenus, with the former being of particular interest to Kyocera.
$1.4M upfront payment paves way for commercial agreement
As part of the MOU, Kyocera will provide an upfront payment of 100 million Japanese yen (~$1.4 million) to Regeneus for the rights to a subset of research knowhow for Progenza. This is a demonstration that Kyocera recognises the potential of Regeneus’ technology platform.
Kyocera will also conduct comprehensive due diligence related to Progenza before progressing to a conditional commercial agreement for the company’s lead technology.
At the conclusion of due diligence, Kyocera will provide an additional 100 million Japanese yen upon meeting the criteria outlined in the agreement, which is refundable if an agreement is not executed.
The upfront payment from Kyocera helps Regeneus expand its pipeline and fund its innovative technology to commercialisation.
Considering osteoarthritis is a $9.5 billion addressable opportunity and Japan alone has more than 30 million patients with osteoarthritis, Regeneus is well positioned to capture the market with this latest announcement.
Latest in string of regenerative medicine deals
Regeneus’ announcement is the latest in a string of successful deals Australian regenerative medicine companies have made with ‘big pharma’ and overseas conglomerates.
For example, Cynata’s 2017 partnership agreement with FujiFilm (like Kyocera, another Japanese giant) for their stem cell therapy product targeting graft versus host disease included a 9 per cent equity and potential future milestone payments. In the time since the announcement, Cynata’s share price has risen almost 19 percent and is now a company worth ~$100M.
Similarly, Mesoblast’s strategic partnership with Grünenthal announced last year to develop an allogenic therapy for low back pain was well received by the market, and the company’s share price has since risen 28 per percent with the company now worth more than $1.2 billion dollars.
Of course, each of these regenerative medicine companies is further along their commercialisation journey. However, it is clear that at just 6 cents, Regeneus is currently under-appreciated by the market despite the significant addressable opportunity for Progenza OA.
Regeneus: closer to commercialisation
This deal moves the under-the-radar regenerative medicine company close towards commercialisation.
As outlined by management in November 2019, the following was the state of play at that stage, indicating that the company has been quick to deliver on its strategy.
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.